PT - JOURNAL ARTICLE AU - Liudmyla Iashyna AU - Yuriy Feshchenko AU - Maryna Polianska AU - Inna Zvol AU - Svitlana Ishchuk AU - Liudmyla Savelieva AU - Alena Potochniak TI - Use of leikotriene modifiers promotes to decrease bronchial hyperreactivity in bronchial asthma patients DP - 2012 Sep 01 TA - European Respiratory Journal PG - P3436 VI - 40 IP - Suppl 56 4099 - http://erj.ersjournals.com/content/40/Suppl_56/P3436.short 4100 - http://erj.ersjournals.com/content/40/Suppl_56/P3436.full SO - Eur Respir J2012 Sep 01; 40 AB - Background: Clinical studies proved, that leikotriene modifiers have mild and variable broncholytic effect, decrease symptoms, improve lung function and decrease asthma exacerbations.Objectives: This study aimed to investigate the influence of leikotriene modifiers (antagonists of CysL-R1 – montelukast) on bronchial hyperreactivity in steriod-naive bronchial asthma patients.Methods: 30 steroid-naive (didn't receive ICS more then 3 months before study) patients, male 9, female 21, in the age (53,4 ± 2,3) years, with ACT score < 20 received montelukast (Lukast) 10 mg OD during 3 months. Salbutamol was allowed as rescue medication. Bronchoprovocative test with physical load (tredmil-test) was performed at the beginning and at the end of the study.Results: Bronchial hyperreactivity (BHR), which revealed in fall of FEV1 on >10% vs basic data after 5 – 30 min after the end of physial load, was revealed in 12 patients. Initially FEV1 falled on 16% on the 5 min after the end of test, with maximal decrease (19,3%) on the 15 min. In 30 min after the end of physsical load FEV1 didn't return to the basic data – difference was 9,5%. At the end of study treatment course BHR was revealed only in 9 patients, with maximal fall 11,5% on 15 min after the test, with recovery within 30 min.Correlative analysis shoved, that risk of BHR decreased after the impermanent course of montelukast therapy, but without stasistical significance.Conclusion: use of leikotriene modifiers (antagonists of CysL-R1 – montelukast (Lukast)) decrease BHR in steriod-naïve BA patients.